Jonathan is the Chief Business Officer at Calico, responsible for supporting the company’s growth by developing innovative scientific collaborations and business partnerships with premier academic institutions and companies in the life science industry. He also has responsibility for overseeing the company’s intellectual property portfolio, business-related legal matters, and portfolio planning and analysis.
Jonathan joined Calico in April 2014 from UCB Pharma, based in Brussels, where he was vice president of global business development, responsible for the company’s worldwide partnering transactions. Prior to UCB, he served as director for the Roche Group responsible for evaluating and leading merger and acquisition transactions. Prior to Roche, as head of oncology business development and in a variety of business development roles over a 10-year period, Jonathan sourced, evaluated, and executed dozens of Genentech’s business development partnerships as well as investments for Genentech’s venture fund. Earlier in his career, Jonathan worked in investment banking in the mergers and acquisitions group at Credit Suisse First Boston in London.
As an early Calico employee, Jonathan helped put in place many key partnerships including groundbreaking collaborations with AbbVie, the Broad Institute, AncestryDNA and C4 Therapeutics. He enjoys leveraging his scientific training and financial experience to support his colleagues in sourcing and implementing exciting scientific, technology and business opportunities for Calico.
Jonathan holds a doctorate in immunology from the University of Oxford where he was a Wellcome Trust Prize Student. He holds a Bachelor of Arts in biological sciences, also from the University of Oxford.